Monday, March 16, 2009
Day 1 - Building Partnerships In Emerging Markets
Today’s economy is encouraging more global deals to be explored, patent strategies to be expanded, and companies to look into new countries without prior deals established.  The Emerging Markets Day At BioNetwork will give you new insight and perspectives into opportunities within previously unidentified companies and their partnering opportunities.

8:00 Networking Breakfast And Registration   

9:00 Chairperson’s Opening Remarks

9:15 Opening Panel Discussion: Effectively Looking For Partnerships Overseas
Christopher Seaton, Senior Vice President, Global Transactions, Bayer
Mark Miller, Senior Director of Corporate Business Development, Eli Lilly
*Reid Leonard, Vice President, External Licensing and Business Development East Coast, Merck

Many companies in today’s market are global, or are expanding their reach to become global, but how do you effectively form profitable partnerships overseas, and where do you begin to search?  This panel discussion will:

• Verify best practices from past experiences to enable future growth potential
• Dig deeper into proven methods for identifying profitable partnerships
• Benchmark past efforts to improve on future partnering opportunities

10:00 Keynote Presentation:  November Election Results – What This Means For Healthcare Pricing And Reimbursement
*Peter Orszag, Director, Congressional Budget Office

The next President of the United States will have to make several important decisions directly impacting drug developers. These decisions will affect federal funding for stem cell research, the lifecycle for biogenerics, and the structure of the nation’s healthcare.  These decisions will greatly impact life sciences companies and this session is designed to address the changes, as well as encourage a dialogue with the audience to discuss the future of drug development. 

10:40 Morning Refreshment Break
Enhance your networking time through poster displays during the morning and afternoon breaks.  A variety of company trade organizations will display their country’s partnering capabilities and aspirations, allowing for diverse conversations with new countries. 

11:25 Case Study:  Japan’s Perspective On U.S. Partnerships – The $8.8 Billion Acquisition of Millennium Pharmaceuticals By Japan’s Takeda
Catherine Sazdanoff, Vice President, Global Licensing, Takeda Pharmaceuticals North America, Inc.
Anna Protopapas, Senior Vice President of Corporate Development, Millennium Pharmaceuticals

12:05 Lunch For All Attendees

1:35 Emerging Markets Roundtable Discussions

Hear from biotech companies in the rising countries within the life sciences industry during these Roundtable Discussions focused on identifying the most promising partnering opportunities within emerging markets across the globe. These targeted discussions will be focused on enabling enhanced networking opportunities specific to the goals of your company.

Table 1 - Asia
Table 2 - Europe – Kia Monteshari, Genfit
Table 3 - India
Table 4 - Canada - *Sanj Singh, Ade Therapeutics

2:45 Afternoon Refreshment Break
Enhance your networking time through poster displays during the morning and afternoon breaks.  A variety of company trade organizations will display their country’s partnering capabilities and aspirations, allowing for diverse conversations with new countries. 

3:30 Case Study: Merck’s Partnerships In India
*Steve Santhadocus, Vice President, Business Development, India, Merck

4:10 Closing Discussion:  Global Patent & Regulatory Strategies
*Mary Till, Legal Advisor, Office of Patent Legal Administration, United States Patent and Trademark Office (pending approval)
John Engel, Partner, Engel & Novit
Len Smith, Senior Intellectual Property Counsel, Novo Nordisk

Patent and regulatory strategies are more prevalent in the issues of today’s market than ever before.  Understanding ownership issues which can arise in patent procurement processes, such as joint research agreements/103(c) and shield/terminal disclaimers, etc. is critical for business development to be involved in.  Understanding how the life science industry deals with, not only FDA, but also the Centers for Medicare and Medicaid Services can help build better business operations to ultimately maintain a flourishing pipeline. 

5:00 Welcome Reception On The Terrace

Tuesday, March 17, 2009
Day 2: Partnering, Funding And Financing In An Unstable Market
Mergers and Acquisitions, In-licensing, Out-licensing, Creative Partnerships, these are all terms popping up more frequently than ever before.  The types of deals being done in today’s economy are very different than deals we have seen in the past.  The discussions and case studies today will examine the new trends and developments being put into place to adapt with this ever-changing economy.

8:00 Networking Breakfast And Registration   

9:00 Chairperson’s Opening Remarks

9:15 Opening Panel Discussion:  Adding Value To A Deal – Utilizing Non Cash Assets Or Creatively Using Cash To Enhance Partnerships
Bruce Halpryn, Senior Director, New Business Development, Technical IP Due Diligence, IP Management, Procter & Gamble
Woody Bryan, Vice President, Business Development, Licensing and Project Management, Supernus Pharmaceuticals, Inc.
Ira Weiss, Vice President of Finance and Operations, BioDtech, Inc.

Deals are not cut and dry like they used to be.  In fact, nothing about traditional deals remains in today’s market.  Companies have to be extremely creative in this eat or be eaten industry.  This panel discussion will challenge past models and engage the audience in discussions on:

• What companies are doing to stay alive in this weak financial market
• Valuing cash vs. expertise and knowledge in prospective partnerships
• Non-traditional sources aiding in today’s deals     
  

10:00 Case Study:  One Company, Two Strategies – Branded and Generic Drugs Working In Harmony
Stephanie Hsieh, Senior Director, Intellectual Property and Legal Affairs, Impax Laboratories
David Paterson PhD, Vice President, Business Development, (Branded) Impax Pharmaceuticals, Inc
*Vice President, Business Development, (Generic) Impax Pharmaceuticals, Inc

10:40 Morning Refreshment Break
Enhance your networking time through poster displays during the morning and afternoon breaks.  A variety of biotech companies and universities will display their partnering capabilities and aspirations, allowing for diverse conversations for future partnerships. 

11:25 Case Study: Building Businesses On Orphan Indications
*Former FDA Orphan Drug Development Director

12:05 Lunch For All Attendees

1:30 Afternoon Roundtable Discussions
Take this chance to sit down with your peers and engage in an informal, candid, and interactive discussion on the issues surrounding the following challenges within Business Development.

How it works:
Each focus area workshop is led by a subject matter expert who will facilitate the discussion among participants.  With one hour devoted to a specific focus area listed below, each participant you will be able to drill down into the most critical challenges while discovering new opportunities.
  
- Valuation
- Virtual Drug Development
- Licensing Diversified Products
- Late Stage Asset Transactions
- Innovative Approaches To Orphan Drugs
- Lifecycle Extension Strategies       

2:30 Afternoon Refreshment Break
Enhance your networking time through poster displays during the morning and afternoon breaks.  A variety of biotech companies and universities will display their partnering capabilities and aspirations, allowing for diverse conversations for future partnerships. 

3:15 Therapeutic Area Partnering Primers
Let us do the work for you by providing introductions to the companies you are looking to meet!
During the Therapeutic Area Partnering Primers you will have the opportunity to hear from biotech companies involved in various therapeutic areas during these partnering primer sessions focused on identifying the most promising partnering opportunities within emerging companies in the outlined therapeutic areas. These ten minute company partnering presentations will be focused on enabling enhanced networking opportunities specific to the goals of your company.
           
- Metabolic - John Celebi, Vice President, Business Development, ArQule, Inc.
- Central Nervous System - Yogish Kamanth, Manager of New Business Development, Intellipharmaceutics
- Infectious Disease - David Wurtman, Vice President, Business Development, NexBio
- Cardiovascular - Iain Dukes, President and CEO, Essentialis
- Oncology - Lesley Stolz, Vice President, Corporate & Business Development, Sunesis Pharmaceuticals, Inc.
- Auto-Immune - Vidal de la Cruz, Vice President, Business Development, Cytokine PharmaSciences, Inc.

4:15 Closing Panel Discussion:  Continuing To Fund Your Portfolio In A Weak Financial Market
Jonathan Montagu, Director, Business Development, Concert Pharmaceuticals
Jim Hattersley, Vice President, Business Development, Antares Pharma
Pavan Handa, Vice President, Business Development, Noven Pharmaceuticals

Companies have to be more creative than ever before in their sources for funding.  Where are these companies looking and how are they achieving this ever obstructing task?  This audience-involved discussion will determine:

• Creative funding sources
• Capital available in the US market vs. overseas
• How to effectively work overseas to remain within your allocated budget
  

5:00 – 6:00 Beach Reception For All Attendees

Wednesday, March 18, 2009
Day 3: Forward Thinking Deal Structures And Industry Progression
Proactive approaches and new models are now the norm for future and present deal structures and business strategies.  These sessions will focus on the future of drug development and explore company structures and forward thinking deals, as well as the impact on your company from the November Presidential election results.  

8:00 Breakfast And Registration          

9:00 Chairperson’s Opening Remarks

9:15 Opening Panel Discussion: Proactive Approaches In Managing The Business Within Alliances
Durga Bobba, Senior Director, Alliance Management, Merck Vaccines
Mike Leonetti, Executive Director, HealthCare Partnerships, Boehringer-Ingelheim
*Mark Barbato, Vice president, Alliance Management, Eli Lilly & Co.

Different company approaches to strategic alliance models can sometimes make all the difference in a partnership.  Determining realistic sales forecasts, outlining strategic marketing plans and the operational outlook on the importance of alliance management are all factors in developing a specific alliance management focus within your organization.  This panel discussion will explore the importance of:

• Not only how the alliance is managed but how the alliance is performing
• Measuring the success of an alliance
• Judging whether the current revenue is of greater importance than partnership

10:00 Case Study:  Novartis/Cerimon
Matt Meyer, Vice President Business Development and Licensing, Cerimon

10:45 Morning Refreshment Break

11:15 Panel Discussion:  New Exit Strategies For Biotech Companies
Thanos Maroglou, Vice President, Business Development, Chimerix Inc.
(Panel currently in development)

12:00 Case Study: Successfully Negotiating Royalties
Ira Weisberg, Vice President, Business Development, Lifecycle Pharma
Matt Reber, Vice President, Business Development, Calin Healthcare Loyalty

12:45 Conclusion Of BioNetwork East 2009